Glucagon-like peptide 1 reverses myocardial hypertrophy through cAMP/PKA/RhoA/ROCK2 signaling

• 作者: Lihui Zhang Qianfeng Xiong Shaohua Fan Xin Zhang Yawei Shi
• 来源期刊: 生物化学与生物物理学报（英文版）
• 关键词: GLP-1 myocardial hypertrophy PKA/RhoA/ROCK2
• 年，卷（期）: 2020,（6）
• 页码范围: 612-619
• 页数: 8页
• 语种: 英文
• DOI: 10.1093/abbs/gmaa038

摘要

Myocardial hypertrophy is a major pathological and physiological process during heart failure.Glucagon-like peptide 1 (GLP-1) is a glucagon incretin hormone released from the gut endocrine L-cells that has protective effects on various cardiovascular diseases,including hypertension,atherosclerosis,and myocardial hypertrophy.However,the protective mechanisms of GLP-1 in myocardial hypertrophy remain unclear.Here,we showed that the GLP-1 agonist liraglutide and dipeptidyl peptidase 4 inhibitor alogliptin decreased heart weight and cardiac muscle cell volume in spontaneously hypertensive rats (SHR).In H9C2 cell hypertensive models induced by angiotensin Ⅱ,GLP-1 treatment reduced myocardial cell volume,inhibited the expressions of atrial natriuretic peptide,brain/B-type natriuretic peptide,β-myosin heavy chain,RhoA,and ROCK2,and decreased MLC and MYPT1 phosphorylation.When H9C2 cells were treated with H89,a PKA inhibitor,the inhibitory effect of GLP-1 disappeared,while the inhibitory role was enhanced under the treatment of Y-27632,a ROCK2 inhibitor.These results suggested that GLP-1 might reverse myocardial hypertrophy through the PKA/RhoA/ROCK2 signaling pathway.